Helping You Build Wealth With Honest Research
Since 1996. Read On...

MEMBER'S LOGIN

MEMBER'S LOGINX

     
Invalid Username / Password
   
     
   
     
 
Invalid Captcha
   
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

Revealed
India's Third Giant Leap

This Could be One of the Biggest Opportunities for Investors




Important: We hate spam as much as you do. Check out our Privacy Policy and Terms Of Use.
By submitting your email address, you also sign up for Profit Hunter, a daily newsletter from Equitymaster
covering exciting investing ideas and opportunities in India.

AD

Midcap & smallcap buck trend
Fri, 27 Sep 01:30 pm

Indian share markets continued to fall in the post-noon trading session. Markets are trading mixed with oil and gas, IT and auto stocks being the biggest gainers. However, banking, realty and metal stocks are the principal losers.

BSE-Sensex is down 101 points and NSE-Nifty is trading 29 points down. BSE Mid Cap is trading up 0.3% and BSE Small Cap index is trading up 0.4%. The rupee is trading at 61.8 to the US dollar.

Majority of automobile stocks are trading in the green, with Hero MotoCorp and Eicher Motors being the major gainers and Mahindra & Mahindra and Tata Motors among the few stocks trading in the red. As per a leading financial daily, Hero MotoCorp is planning to introduce over 15 new offerings by the end of FY14. A majority of the offerings will be launched in the December 2013 quarter that coincides with the festive season in India. The offerings include a revamped version of the high-end bike Karizma which has been re-designed and has a more powerful engine. This commercial production model has been co-jointly developed with US-based partner Erik Buell Racing. The company expects demand to be robust in the festive season on the back of good monsoon and recent RBI announcement. Since Hero MotoCorp ended its partnership with Honda in 2010, the company has been working towards developing its own technology as well expanding operations in the overseas markets. The stock is currently trading up by 2.3%.

Most of the Indian pharma stocks are trading in the green with Aurobindo pharma and Orchid chemicals among the leading gainers.  As per the financial daily, Sun pharmaceuticals is expected to gain higher market share in Doxyrubicin sold in US. In US, other than Sun only Johnson and Johnson (J&J) supplies this drug under the brand Doxil. The said drug has faced shortage problems in past in the US market. Recently, J&J has once again announced about the shortage of the drug in US market. This is due to an interruption of supply from the company's own suppliers, Ben Venue Labs. Reportedly, from Oct 2013 onwards, the supply from J&J will come down which might give rise to shortage situation in US. In FY13, when J&J was facing manufacturing constraints, this drug had contributed around $100 m sales to Sun’s business. The current shortage of this drug will help Sun pharma to fetch better market share. Sun pharma is trading up by 1.5%.

For information on how to pick stocks that have the potential to deliver big returns, download our special report now!

View all commentaries | Archives

Read the latest Market Commentary


Equitymaster requests your view! Post a comment on "Midcap & smallcap buck trend". Click here!

  
ABOUT EQUITYMASTER

Since 1996, Equitymaster has been the source for honest and credible opinions on investing in India. With solid research and in-depth analysis Equitymaster is dedicated towards making its readers- smarter, more confident and richer every day. Here's why hundreds of thousands of readers spread across more than 70 countries Trust Equitymaster.

PREMIUM PRODUCTS
QUICK LINKS
POPULAR TOPICS
TRENDING TOPICS
FREE NEWSLETTERS
EQUITYMASTER SUPPORTS
  • HelpYourNGO
  • You Tube
  • Linkedin
  • Twitter
  • Telegram
  • Google Play

Copyright © Equitymaster Research Private Limited (formerly Equitymaster Agora Research Private Limited).

Whitelist | Refer | Terms | Privacy | Contact | About | Sitemap

Phone +91-9136015013

Equitymaster Research Private Limited (formerly Equitymaster Agora Research Private Limited) (Research Analyst)
SEBI (Research Analysts) Regulations 2014, Registration No. INH000000537.

103, Regent Chambers, Above Status Restaurant, Nariman Point, Mumbai - 400 021. India.
Telephone: +91-22-61434055. Email: info@equitymaster.com. Website: www.equitymaster.com.
CIN:U74999MH2007PTC175407

Name of the Compliance & Grievance Officer: Ms Sonal Ramachandran
Telephone: +91-22-61434003 | Email: compliance@equitymaster.com

LEGAL DISCLAIMER:
Investment in securities market are subject to market risks. Read all the related documents carefully before investing.
Registration granted by SEBI and certification from NISM in no way guarantee performance of the intermediary or provide any assurance of returns to investors.

All rights reserved. Any act of copying, reproducing or distributing this newsletter whether wholly or in part, for any purpose without the permission of Equitymaster is strictly prohibited and shall be deemed to be copyright infringement.

Equitymaster Research Private Limited (formerly Equitymaster Agora Research Private Limited) (Research Analyst) bearing Registration No. INH000000537 (hereinafter referred as 'Equitymaster') is an independent equity research Company. Equitymaster is not an Investment Adviser. Information herein should be regarded as a resource only and should be used at one's own risk. This is not an offer to sell or solicitation to buy any securities and Equitymaster will not be liable for any losses incurred or investment(s) made or decisions taken/or not taken based on the information provided herein. Information contained herein does not constitute investment advice or a personal recommendation or take into account the particular investment objectives, financial situations, or needs of individual subscribers. Before acting on any recommendation, subscribers should consider whether it is suitable for their particular circumstances and, if necessary, seek an independent professional advice. This is not directed for access or use by anyone in a country, especially, USA, Canada or the European Union countries, where such use or access is unlawful or which may subject Equitymaster or its affiliates to any registration or licensing requirement. All content and information is provided on an 'As Is' basis by Equitymaster. Information herein is believed to be reliable but Equitymaster does not warrant its completeness or accuracy and expressly disclaims all warranties and conditions of any kind, whether express or implied. Equitymaster may hold shares in the company/ies discussed herein. As a condition to accessing Equitymaster content and website, you agree to our Terms and Conditions of Use, available here. The performance data quoted represents past performance and does not guarantee future results.